CompletedNCT03319953
TAK-041 or Placebo Added to Antipsychotics for Schizophrenia
About this title
Read the official source — NCT03319953Medication studyAges 18–60United Kingdom
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- LondonSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: December 21, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 23
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT03319953
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With Stable Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Did this study involve medication?
Yes. The study involved medication, including TAK-041, Placebo and Second Generation Antipsychotics (SGA).
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
